Vous avez cherché: daklatazvir (Croate - Anglais)

daklatazvir
daclatasvir

simeprevir daklatazvir
(co-formulated with

daklatazvir/dolutegravir
daclatasvir/dolutegravir

daklatazvir + pegifn/rbv
daclatasvir + pegifn/rbv

djelatna tvar je daklatazvir.
the active substance is daclatasvir.

c  45% daklatazvir 
c  45% daclatasvir 

daklatazvir inhibira p-gp.
p-gp inhibition by daclatasvir

daklatazvir auc: ↔* cmax: ↔* cmin: ↔
daclatasvir auc: ↔* cmax: ↔* cmin: ↔*

daklatazvir + sofosbuvir 12 tjedana
daclatasvir + sofosbuvir 12 weeks

daklinza 30 mg tablete daklatazvir
daklinza 30 mg tablets daclatasvir

daklatazvir inhibira oatp1b1 i bcrp.
inhibition of oatp 1b1 and bcrp by daclatasvir

daklatazvir inhibira p-gp i bcrp.
inhibition of p-gp and bcrp by daclatasvir

(daklatazvir 20 mg jedanput na dan)
telaprevir 500 mg q12h (daclatasvir 20 mg once daily)

daklinza sadrži djelatnu tvar daklatazvir.
daklinza contains the active ingredient daclatasvir.

daklinza 30 mg filmom obložene tablete daklatazvir
daklinza 30 mg film-coated tablets daclatasvir

budući da daklatazvir inhibira p-gp, očekuje se:
expected due to inhibition of p-gp by daclatasvir:

daklatazvir inhibira i replikaciju virusne rnk i sklapanje viriona.
daclatasvir inhibits both viral rna replication and virion assembly.

budući da daklatazvir inhibira oatp 1b1 i/ili bcrp, očekuje se:
expected due to inhibition of oatp 1b1 and/or bcrp by daclatasvir:

daklatazvir nije promijenio koncentraciju dolutegravira u plazmi u klinički relevatnoj mjeri.
daclatasvir did not change dolutegravir plasma concentration to a clinically relevant extent.

ciklosporin u pojedinačnoj dozi od 400 mg (daklatazvir 60 mg jedanput na dan)
cyclosporine 400 mg single dose (daclatasvir 60 mg once daily)